Insulin icodec for treating Type 1 and Type 2 diabetes


featured image

Insulin icodec is currently in clinical development for the treatment of Type 1 (T1D) and Type 2 (T2D) diabetes mellitus.

Interventions: Insulin icodec
Year: 2022

Insulin icodec is currently in clinical development for the treatment of Type 1 (T1D) and Type 2 (T2D) diabetes mellitus. Diabetes mellitus is a condition where blood glucose levels are too high due to an issue with either insulin production (T1D) or insulin resistance (T2D). Insulin is a hormone that controls blood glucose levels. T1D occurs due to an autoimmune response against pancreatic cells that produce insulin whilst T2D occurs when cells no longer react to insulin in the correct way – both result in high glucose levels which can cause severe dehydration, diabetic comas, vision problems and permanent damage to nerves, kidneys, and blood vessels. Current treatment requires daily insulin injections which can hinder adherence to treatment and be a burden to individuals.